跳至主要内容
临床试验/NCT03207646
NCT03207646终止不适用

Smartphone GUIded MeDication AdherencE and Rehabilitation in Patients With Coronary Artery Disease (smartGUIDE)

Stanford University2 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2017年7月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
63
试验地点
2
主要终点
Medication adherence

研究概览

简要总结

This study evaluates a smartphone-based cardiac rehabilitation program in adults with coronary artery disease. Half of patients will participate in a smartphone-based cardiac rehabilitation program while the other half will receive standard-of-care.

详细描述

Cardiac rehabilitation as a means to improve lifestyle-based risk factor modification, remains poorly prescribed and utilized, often due to the lack of access to programs, poor insurance coverage, cost, or patient or physician motivational factors. Low-cost solutions that can improve patient adherence to medications, risk factor reduction, and exercise could improve cardiovascular outcomes and cost-effectiveness compared to current care models.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

smartphone-based cardiac rehabilitation

Experimental

The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.

干预措施: BrightHeart® (Other)

Control

No Intervention

Standard-of-care alone.

结局指标

主要结局

Medication adherence

时间窗: Baseline through End of Study visit - approximately 90 days per participant.

The proportion of days coverd (PDC) expressed as a percentage but considered as a continuous variable of the composite of the prescribed P2Y12 receptor antagonist and/or the statin.

次要结局

  • Medication adherence III(Baseline through End of Study visit - approximately 90 days per participant.)
  • Cardiovascular risk factors VI(Baseline through End of Study visit - approximately 90 days per participant.)
  • Medication adherence II(Baseline through End of Study visit - approximately 90 days per participant.)
  • Cardiovascular risk factors I(Baseline through End of Study visit - approximately 90 days per participant.)
  • Cardiovascular risk factors II(Baseline through End of Study visit - approximately 90 days per participant.)
  • Cardiovascular risk factors III(Baseline through End of Study visit - approximately 90 days per participant.)
  • Exploratory I: Rehospitalization(Baseline through End of Study visit - approximately 90 days per participant.)
  • Medication adherence IV(Baseline through End of Study visit - approximately 90 days per participant.)
  • Medication persistence(Baseline through End of Study visit - approximately 90 days per participant.)
  • Medication adherence V(Baseline through End of Study visit - approximately 90 days per participant.)
  • Cardiovascular risk factors IV(Baseline through End of Study visit - approximately 90 days per participant.)
  • Cardiovascular risk factors V(Baseline through End of Study visit - approximately 90 days per participant.)
  • Cardiovascular risk factors VII(Baseline through End of Study visit - approximately 90 days per participant.)
  • Exploratory II: Cardiovascular outcomes(Baseline through End of Study visit - approximately 90 days per participant.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mintu Turakhia

Associate Professor of Cardiovascular Medicine

Stanford University

研究点 (2)

Loading locations...

相似试验